Physician profile
Kelly A Jackson
NPI 1841780178
$26,516.57
in general payments reported to CMS, 2019-2025
43 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,966 · 2022: $2,826 · 2023: $3,638 · 2024: $1,990 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,818 · Consulting Fee: $6,100 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,075 · Travel and Lodging: $2,723 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,818.20 |
| Consulting Fee | $6,100.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,075.00 |
| Travel and Lodging | $2,722.76 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $10,514.38 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management, General - Therapies |
| Abbvie INC. | $10,280.81 | 2021-2025 | |
| Nevro Corp. | $1,393.80 | 2021-2024 | Senza |
| Amgen INC. | $519.91 | 2021-2023 | Prolia, Evenity |
| Collegium Pharmaceutical, INC. | $512.88 | 2022-2025 | Belbuca, Xtampza |
| Biohaven Pharmaceutical Holding Company Ltd. | $335.21 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $307.15 | 2021-2025 | Relistor |
| Lundbeck LLC | $281.33 | 2021-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $259.94 | 2021-2023 | Austedo Xr, Austedo |
| Pfizer INC. | $252.31 | 2023-2025 | |
| Abbott Laboratories | $215.80 | 2021-2024 | Eterna |
| Curonix LLC | $209.61 | 2022-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Vertos Medical, INC. | $132.75 | 2024 | Mild Device Kit |
| Genentech USA, INC. | $113.99 | 2021 | |
| Scilex Pharmaceuticals INC. | $102.56 | 2022-2023 | Ztlido |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.